Reactivity and Increased Proliferation of NG2 Cells Following Central Nervous System Infection with Theiler's Murine Encephalomyelitis Virus

Laura A. Bell¹,², Glenna J. Wallis¹, and Karen S. Wilcox¹,²,*

¹Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT 84112, USA.
²Interdepartmental Program in Neuroscience, University of Utah, Salt Lake City, UT 84112, USA.

*Author for Correspondence. Email: karen.wilcox@hsc.utah.edu
Abstract

Background: Neuron-Glial Antigen 2 (NG2) cells are a glial cell type tiled throughout the grey and white matter of the Central Nervous System (CNS). NG2 cells are known for their ability to differentiate into oligodendrocytes and are commonly referred to as oligodendrocyte precursor cells. However, recent investigations have begun to identify additional functions of NG2 cells in CNS health and pathology. NG2 cells form physical and functional connections with neurons and other glial cell types throughout the CNS, allowing them to monitor and respond to the neural environment. Growing evidence indicates that NG2 cells become reactive under pathological conditions, though their specific roles are only beginning to be elucidated. While reactive microglia and astrocytes are well-established contributors to neuroinflammation and the development of epilepsy following CNS infection, the dynamics of NG2 cells remain unclear. Therefore, we investigated NG2 cell reactivity in a viral-induced mouse model of temporal lobe epilepsy.

Methods: C57BL6/J mice were injected intracortically with Theiler's Murine Encephalomyelitis Virus (TMEV) or PBS. Mice were graded twice daily for seizures between 3–7 days post-injection (dpi). At 4 and 14 dpi, brains were fixed and stained for NG2, the microglia/macrophage marker IBA1, and the proliferation marker Ki-67. Confocal z-stacks were acquired in both the hippocampus and the overlying cortex. Total field areas stained by each cell marker and total field area of colocalized pixels between NG2 and Ki67 were compared between groups.

Results: Both NG2 cells and microglia/macrophages displayed increased immunoreactivity and reactive morphologies in the hippocampus of TMEV-injected mice. While increased immunoreactivity for IBA1 was also present in the cortex, there was no significant change in NG2 immunoreactivity in the cortex following TMEV-infection. Colocalization analysis for NG2 and Ki-67 revealed a significant increase in overlap between NG2 and Ki-67 in the hippocampus of TMEV-injected mice at both timepoints, but no significant differences in cortex.
Conclusions: NG2 cells acquire a reactive phenotype and proliferate in response to TMEV-infection. These results suggest that NG2 cells alter their function in response to viral encephalopathy, making them potential targets to prevent the development of epilepsy following viral infection.

Keywords
Epilepsy, NG2, Glia, Gliosis, Microglia, Viral Infection, Encephalitis, Theiler murine encephalomyelitis virus (TMEV).

Introduction
Temporal lobe epilepsy (TLE) is the most common form of acquired epilepsy and can develop following numerous insults to the central nervous system (CNS), including viral infection. Viral encephalitis is commonly associated with seizures and increases the risk of developing epilepsy by more than 20% over the general population (1–3). A variety of neurotropic viruses cause encephalitis and are suggested to play a role in the development of seizures and epilepsy in humans, including human herpes virus (HHV), herpes simplex virus (HSV), Japanese encephalitis virus (JEV), Nipah virus, West Nile virus, enterovirus, Toscana virus, chikungunya virus, human immunodeficiency virus (HIV), influenza A and B, rotavirus, adenovirus, respiratory syncytial virus, cytomegalovirus, and severe acute respiratory syndrome coronavirus (SARS-CoV-2) (1–4).

The Theiler’s murine encephalomyelitis virus (TMEV) mouse model of TLE is the only well-characterized model of viral encephalitis-induced epilepsy that recapitulates the sequence of epilepsy pathogenesis seen in humans, including survival of the acute infection and a majority of animals that later develop spontaneous recurrent seizures after a seizure-free latent period.
Intracortical injection of the Daniels’ strain of TMEV into a specific strain of mouse (C57BL/6J) leads to acute encephalitic seizures from 3 to 8 days post injection (dpi) (5,6). Although the virus is cleared from the brain by around 14 dpi, a significant portion (>50%) of mice go on to later develop epilepsy starting around 2-months post-infection (5,7,8).

Approximately 30-40% of epilepsy patients remain refractory to therapy, indicating a substantial need to identify new targets for anti-seizure or anti-epileptogenic treatments (9–11). While aberrant hyperexcitability and hypersynchronization of neurons are hallmarks of seizure activity, the presence of reactive glial cells or glial scar formation is nearly universal within epileptic lesions or foci. CNS glia, including astrocytes, microglia, neuron-glial antigen 2-expressing cells (NG2 cells), and oligodendrocytes are intricately involved in diverse neural functions, including neurotransmitter buffering, ion and water homeostasis, axon insulation, synapse function and plasticity, and blood-brain-barrier (BBB), extracellular matrix (ECM), and immune system regulation. It is now well-established that glial functions are commonly altered or disrupted in the process of epileptogenesis. Therefore, glial cells have come under recent focus as potential targets to promote homeostasis and functional recovery after a seizure or initiating epileptogenic event (12–16).

NG2 cells are a glial cell type abundantly tiled throughout the adult CNS. Due to their capacity to generate and regenerate oligodendrocytes during development and adulthood, they are often referred to as oligodendrocyte precursor cells (OPCs). However, a growing body of evidence indicates much broader and more complex roles for NG2 cells in nervous system function and disease and has led to their classification as the fourth major glial cell type (17–20). NG2 cells receive both inhibitory and excitatory synaptic inputs and express a distinguishing array of ion channels, receptors, and an immunoproteasome, uniquely priming them to monitor and respond to changes in the neural environment (19,21–25).
In the TMEV model of TLE, TMEV infects hippocampal pyramidal neurons producing moderate to severe hippocampal necrosis and initiating seizure development (6–8,26). Glia cells, including astrocytes and microglia, respond to contain and to mitigate damage, but NG2 cell participation has not been determined. Previous studies from our lab have identified microglia as crucial regulators of the inflammatory response and astrocytes as active participants in synaptic remodeling following TMEV infection (5,7,26–28). Reactive glia undergo metabolic and functional changes, including increased phagocytosis to clear debris, increased proliferation to amplify glial cell numbers, formation of a glial scar to seal off damage, increased production of proinflammatory cytokines to encourage defensive behaviors in neighboring cells, and morphologic hypertrophy by increasing glial cell size and/or surface protein expression. Therefore, in the present study, we investigated how NG2 cells respond to TMEV encephalitis at 4 and 14 days post-infection by examining NG2 cell hypertrophy, proliferation, and scar formation in the necrotic hippocampal region and in the non-directly affected cortex. Identifying the role of NG2 cells in epilepsy pathogenesis following viral encephalitis may lead to novel targets to block prolonged inflammatory response and to promote homeostasis and tissue repair.

Materials and methods

Animals

Male and Female C57BL/6 mice aged between 4-5 weeks old were purchased from Jackson Laboratory (Bar Harbor, ME, USA). Mice were acclimatized for one week prior to the experiments. Mice were provided food (Teklad Global Soy Protein-Free Extruded Rodent Diet cat. #2920X; Harlan Laboratories) and water ad libitum and housed in a temperature- and light-controlled (12 hour light/dark cycle) environment. All procedures were performed in accordance with the
TMEV Infection and Seizure Monitoring

Mice were anesthetized briefly using a mixture of isoflurane and compressed air. Mice were then injected with 20 µl of either phosphate-buffered saline (PBS, n=8) or 2.5 x 10⁵ plaque forming units of Daniels strain of TMEV (n=16) intracortically to a depth of 2 mm in the right hemisphere of the posterior parietal cortex as previously described (29–31). Animals were monitored for handling-induced behavioral seizures and body weight changes twice daily from 3 to 7 dpi between the hours of 9am and 6pm. Mice were agitated by briefly shaking their cages, and the intensity of the seizure activity was graded using a modified Racine scale as follows: Stage 1, mouth and facial movements; Stage 2, head nodding; Stage 3, forelimb clonus; Stage 4, forelimb clonus with rearing; Stage 5, rearing and falling; Stage 6, rearing and falling with extensive jumps or severe hindlimb clonus (32). Mice were included in histological analysis only if they were observed to have at least one seizure of a Racine score of 3 or greater. TMEV-infected mice and PBS-controls were sacrificed at 4 dpi (PBS, n=4; TMEV, n=8) and 14 dpi (PBS, n=4; TMEV, n=8). These two time points were chosen as they represent times post-infection when animals begin to have seizures (4 dpi) and after seizures remit and the virus is largely cleared (14 dpi). In addition, previous work from our lab has used those time points to assess microglia and astrocyte reactivity (31).

Immunofluorescence

Animals were anesthetized through intraperitoneal injection with pentobarbital, and transcardial perfusions were performed with PBS followed by 10% neutral buffered formalin solution (NBF). Brains were then postfixed 12-18 hours in 10% NBF and transferred to a 15%/30% sucrose gradient for cryoprotection. Tissue was frozen and sectioned coronally to 30 µm on a freezing
stage microtome (Leica, Buffalo Grove, IL). Slides were mounted with triplicate sections from both a PBS and TMEV brain as well as one section from each brain for a primary antibody-omission control to confirm antibody specificity on each slide. A hydrophobic barrier pen (Vector Laboratories H-4000) was used to separate the two control sections from the six stained sections. Slides were washed 3 times with PBS and blocked in CytoQ ImmunoDiluent & Block Solution (Innovex NB307-C) containing 0.3% Tween-20 for 1 hour. Tissue was incubated overnight at 4°C with primary antibodies directed to NG2 (Millipore/Sigma AB5230, 1:250), ionized calcium-binding adaptor molecule 1 (IBA1) (Novus Biologicals NB100-1028, 1:500), or Ki-67 (R&D Systems AF7649, 1:65) diluted in CytoQ ImmunoDiluent & Block Solution containing 0.05% Tween-20. Sections were then washed five times with CytoQ containing 0.1% Tween-20 and incubated for 2 hours at room temperature with secondary antibodies, respectively, AlexaFluor donkey anti-rabbit 488, AlexaFluor donkey anti-goat 546, or AlexaFluor donkey anti-sheep 555. Slides were counterstained with DAPI (D9542, Sigma Aldrich). Slides were then rinsed five times with PBS and mounted with Prolong Gold antifade reagent (Molecular Probes) using No. 1.5 coverslips.

**Imaging and Analysis**

Images were captured with a Nikon A1 confocal microscope (Nikon Instruments, Melville, NY) at the University of Utah Cell Imaging Core Facility using a 20x/NA 1.0 air objective. Laser output, photomultiplier, and offset settings were adjusted to minimize saturated pixels and maximize contrast across samples. Once optimized, the laser settings were held constant between images acquired from control and TMEV-infected sections across all slides. Regions of interest, including the right dorsal CA1 region of the hippocampus and the overlying cortex, were initially identified using epifluorescence in the DAPI channel. Once a region was selected, laser-scanning mode was used to acquire 12 x 1 μm z-stack optical images for each brain from triplicate sections using Nikon’s Confocal NIS-Elements Acquisition Software.
Raw grayscale 12-bit images from the channel of each marker were processed to perform comparative fluorescence and colocalization analysis using ImageJ software (National Institutes of Health, Bethesda, MD). Each image was first converted to 8-bit then processed using the “Stack Contrast Adjustment” plug-in by manually selecting the image with the highest contrast as the reference image for each stack (33). An automated macro was created to perform the following functions to the stack contrast adjusted images in batch: A rolling ball background subtraction was performed and resulting images were processed using the “Hybrid 3D median Filter” plug-in (34). Images containing NG2 and IBA1 stains were thresholded by setting a global threshold (value=30). Images containing Ki-67 were thresholded at 0.35% stack histogram. For colocalization analysis, the corresponding images from each channel were processed through the “colocalization” plug-in (35). Total field areas stained by each marker, as well as the total field area of the colocalized points between NG2 and Ki-67, were measured for each optical section through the stained tissue section. These values were averaged for each tissue section and then averaged across the triplicate sections stained from each brain.

For all representative images, brightness and contrast were adjusted linearly across the entire image to remove background and maximize contrast. For representative images showing comparison of IBA1 or NG2, the brightness and contrast levels for each channel were held constant between images. For representative images showing Ki-67, the Ki-67 channel was set to 0.35% histogram for each image to remove background and lower levels of expression in quiescent cells, such as neurons (36).

**Statistics**

Total field area per stain was compared between brains from control and seized groups (PBS-injected vs. TMEV-injected) using two-tailed unpaired t-tests. All data are presented with the mean value (x), the median value (middle line) and 25th to 75th percentiles. All statistical analysis was
performed using MATLAB, and figures were prepared using Adobe Illustrator. \( P \) values less than 0.05 were considered statistically significant.

**Results**

**Acute behavioral seizures in TMEV-infected mice**

The majority of behavioral seizures occur between 3 and 7 dpi in the TMEV model (5). Accordingly, we monitored behavioral seizures twice per day between 3 and 7 dpi. Because it is not possible to predict which animals will develop seizures, the number of animals was doubled for the TMEV group (n=16). Cumulatively, 93.75% of TMEV-infected animals were observed to have at least one seizure prior to sacrifice (Fig. 1A). However, during the observation periods on any given day, the percentage of animals that showed stage 3 or greater seizure activity ranged from 37 – 87% (Fig. 1B). As previously described, seizure severity increased over the course of the observation periods, with the majority of seizures observed being either stage 5 or stage 6 by 6 dpi (Fig. 1C). Only animals that exhibited at least one stage 3 or greater seizure during the observation periods were used for further analysis. No seizures were observed in PBS-injected animals throughout the course of the study.

**NG2 cells become reactive in the hippocampus, but not the cortex, of TMEV-infected mice**

Following TMEV infection, reactive astrocytes and microglia/macrophages have been observed in the CA1 region of the hippocampus and in the cortex (31). Reactivity of glial cells was also shown to persist well after viral clearance (≥ 14 dpi) (1,5,7,29–31). We aimed to build upon these findings and determine whether NG2 cells display a similarly reactive phenotype. We used immunohistochemistry at discrete time points post-TMEV infection to analyze immunoreactivity of anti-NG2 antibody for NG2 cells and anti-IBA1 antibody for microglia/macrophages. While IBA1 cannot discriminate between microglia and infiltrating macrophages, it does provide exceptional
visualization of cell morphology. Therefore, quantitative analysis of IBA1 is used as a measure of changes in both the density and morphology of microglia as well as the infiltration of macrophages. Figure 2 shows a wide-field example of regions of interest in a TMEV-infected mouse at 4 dpi. We found the area positive for NG2 and IBA1 was significantly elevated in the CA1 hippocampal region of TMEV-injected mice at both 4 dpi (NG2 p=0.0136 and IBA1 p=0.0140) and 14 dpi (NG2 p=0.0493 and IBA1 p=0.0015) compared to PBS-injected controls (Fig. 3A-C and Fig. 4A-C). NG2 cell reactivity was also qualitatively confirmed based on morphological changes including hypertrophy of NG2 cell soma and processes (Fig. 3A and Fig. 4A) and their presence within the glial scar formation at 14 dpi (Fig. 4A).

In agreement with previous studies, significantly elevated IBA1 immunoreactivity was also present in the cortex of TMEV-infected mice compared to PBS-injected controls at both 4 dpi (p=0.00001) (Fig. 5A,C) and 14 dpi (p=0.0030) (Fig. 6A,C) (31). However, analysis of NG2 immunoreactivity in the cortex revealed no significant difference between TMEV- and PBS-injected mice at either 4 dpi (p=0.5405) (Fig. 5A-B) or 14 dpi (p=0.9119) (Fig. 6A-B). These results suggest that NG2 cell reactivity is more localized to the hippocampal site of active infection and seizure focus compared to microglia/macrophages.

**Increased proliferation of NG2 cells in the hippocampus**

Glial activation and scar formation during CNS insult and epileptogenesis often coincide with increases in glial proliferation (15,16,31). It was previously shown that both astrocytes and microglia undergo increased proliferation at 4 dpi in the TMEV model (31). In order to determine whether NG2 cells also undergo increased proliferation in response to TMEV infection, we performed colocalization analysis to identify cells expressing both proliferation marker Ki-67 and NG2 (37). A significant increase in overlap between NG2 and Ki-67 was observed at both 4 dpi (p=0.0021) and 14 dpi (p=0.0057) in the CA1 region of the hippocampus of TMEV-injected animals (Fig. 7A-C). The levels of colocalization between NG2 and Ki-67 did not differ significantly
in the cortex between TMEV-injected animals and PBS-injected controls at either 4 dpi (p=0.0757) or 14 dpi (p=0.1606) (Fig. 7A-C). This data suggests that there is ongoing increased proliferation of NG2 cells in the hippocampus, but not cortex, following TMEV infection.

Discussion

This study is the first to evaluate the effect of TMEV infection and seizures on the activation state of NG2 cells using IHC techniques. Quantitative analysis revealed reactivity of both NG2 cells and microglia/macrophages in the CA1 region of TMEV-injected brains at 4 and 14 dpi as measured by significantly greater immunoreactivity of NG2 and IBA1, respectively. Our data adds NG2 cells to the repertoire of reactive cell types and participants in glial scar formation in response to TMEV-infection and replicates previous studies identifying reactive microglia/macrophages in both the hippocampus and cortex (31). NG2 cells express a wide array of Ca\(^{2+}\) channels and receptors that regulate diverse aspects of NG2 cell morphology and function, including immune signaling, process dynamics, cell migration, intercellular communication, and release of trophic and secreted factors (25). Reactive NG2 cells displayed characteristic thick and ramified processes, reinforcing the possibility that NG2 cells, like other glia, likely undergo altered gene expression and physiological changes that coincide with the observed morphological changes following CNS infection (24,25,38,39).

We also observed increased proliferation of NG2 cells in the CA1 region of TMEV-infected brains. While NG2 cells are the most proliferative cells in the healthy adult brain, increased NG2 cell proliferation has been demonstrated following several types of CNS injury (40–44). It is noteworthy that, unlike microglia, enhanced NG2 cell reactivity and proliferation appeared to localize tightly to the CA1 region of the hippocampus, the site of active infection and significant neuronal cell death in the TMEV-model (5,6,31). Additionally, while previous studies found that
initial increases in proliferation of microglia/macrophages and astrocytes diminished to undetectable levels by 14 dpi, increased proliferation of NG2 cells observed at 4 dpi was sustained at the 14 dpi timepoint (31). This prolonged increase in proliferation suggests that NG2 cells may play a role in the ongoing innate immune response and scar formation following TMEV infection.

Glial cells dynamically sense and respond to the neural environment. Upon an initiating neurological insult or injury, reactive astrocytes, microglia, and NG2 cells have been demonstrated to secrete pro-inflammatory cytokines in order to adapt to damage and promote homeostasis. However, in cases of chronic epilepsy, the release of pro-inflammatory cytokines can become harmful, contributing to neuronal hyperexcitability and the generation of seizures (45,46). Several studies have identified immune antigen-presentation on NG2 cells in response to neurological insult or injury, suggesting NG2 cells may play a role in the inflammatory milieu contributing to seizures following TMEV-infection (21,27,32,47,48). Conversely, NG2 cells have also been shown to suppress neuroinflammation and microglial activation through TGF-β signaling (24). These diametric findings suggest that reactive NG2 glia may assume immune-promoting or immune-suppressing roles in a context-specific manner. Untangling the signaling pathways involved in NG2 cell immunomodulation may provide new therapeutic targets aimed at tipping the balance of an uncontrolled or prolonged neuroimmune response following viral infection.

Several reports also provide evidence that reactive NG2 cells within the vicinity of injury sites function to form a barrier around damaged tissue in order to protect the surrounding healthy tissue (42,49). A recent study by Damisah et al. demonstrate that microglia, astrocytes, and NG2 cells coordinate their response to clear damaged and dying neurons, with NG2 cells not only polarizing towards dying neurons, but remaining to fill the lesion after removal of neuronal debris was complete (50). While the exact purpose of NG2 cell activity in formation of the glial scar remain unclear, increased expression or deposits of NG2, otherwise known as chondroitin sulfate proteoglycan 4 (CSPG4), may form a barrier to repair damage in epilepsy-inducing lesions and
significantly alter the function of surviving neurons and astrocytes, contributing to epileptogenesis (16). Because NG2 cell reactivity is spatially restricted to the site of active infection and seizure focus, deciphering their specific functions within the scar could provide novel insights into mechanisms underlying epileptogenesis.

Together, our data show robust NG2 cell activation and proliferation in response to TMEV-infection and acute seizures. NG2 cells are increasingly being recognized as important players in promoting CNS health and pathology. While the exact function of NG2 cell reactivity in response to TMEV-infection is still unknown, the combination of advanced RNA-sequencing technologies along with functional imaging approaches using genetically encoded calcium indicators can be used to target the role of NG2 cells in the process of epileptogenesis. While most currently available antiseizure drugs target neuronal mechanisms, 30-40% of epilepsy patients remain refractory to currently available therapies. Identifying the role of NG2 cells in epilepsy pathogenesis following viral encephalitis may lead to novel targets and strategies towards blocking prolonged inflammatory response and facilitating therapies designed to promote homeostasis and tissue repair.

Conclusions

In summary, our study identifies reactive NG2 cells in the inflamed and epileptogenic hippocampus following CNS infection with TMEV, indicating that NG2 cells are involved in the neuroinflammatory response and may be promising targets for preventing seizures and epilepsy following viral infection.

Abbreviations
NG2: Neuron-glial antigen 2

CNS: Central nervous system

TMEV: Theiler's murine encephalomyelitis virus

PBS: Phosphate buffered saline

NBF: Neutral buffered formalin

Dpi: Days post-injection

IBA1: Ionized calcium binding adaptor molecule 1

TLE: Temporal lobe epilepsy

HHV: Human herpes virus

HSV: Herpes simplex virus

JEV: Japanese encephalitis virus

HIV: Human immunodeficiency virus

SARS-CoV-2: Severe acute respiratory syndrome coronavirus

BBB: Blood-brain barrier

ECM: Extracellular Matrix

OPC: Oligodendrocyte precursor cell

IHC: Immunohistochemistry

CA1: cornu Ammonnis subfield 1

TGF-β: Transforming growth factor beta

CSPG4: chondroitin sulfate proteoglycan 4
Declarations

Ethics approval and consent to participate

All procedures were performed in accordance with the National Institutes of Health *Guide for the Care and Use of Laboratory Animals* and approved by the Institutional Animal Care and Use Committee of the University of Utah (IACUC no: 18-02007).

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analyzed in the present study are available from the corresponding author upon reasonable request.

Competing interests

The authors declare that they have no competing interests.

Funding

This work was supported by NIH/NINDS R37NS065434 (KSW). L.A.B. was supported by the NSF Graduate Fellowship Program (GRFP). G.J.W. was supported by the Skaggs Graduate Research Fellowship.

Authors’ contributions
L.A.B, G.J.W., and K.S.W. conceived of the study. L.A.B. performed the experiments, analyzed the results, and wrote the manuscript. G.J.W, and K.S.W. commented on the results, and revised the manuscript. The final manuscript was approved by all authors.

**Acknowledgements**

We thank the University of Utah Cell Imaging Core Facility for microscopy support. We thank Lauren Buxton for animal care and technical assistance.

**References**

1. Libbey JE, Fujinami RS. Neurotropic viral infections leading to epilepsy: Focus on Theiler’s murine encephalomyelitis virus. Future Virol. 2011;6(11):1339–50.

2. Misra UK, Tan CT, Kalita J. Viral encephalitis and epilepsy. Epilepsia. 2008;49(SUPPL.6):13–8.

3. Getts DR, Balcar VJ, Matsumoto I, Müller M, King NJC. Viruses and the immune system: Their roles in seizure cascade development. J Neurochem. 2008;104(5):1167–76.

4. Asadi-Pooya AA. Seizures associated with coronavirus infections. Vol. 79, Seizur. 2020.

5. Stewart KAA, Wilcox KS, Fujinami RS, White HS. Development of postinfection epilepsy after theiler’s virus infection of C57BL/6 mice. J Neuropathol Exp Neurol. 2010;69(12):1210–9.

6. Libbey JE, Kirkman NJ, Smith MCP, Tanaka T, Wilcox KS, White HS, et al. Seizures following picornavirus infection. Epilepsia. 2008;49(6):1066–74.

7. Kirkman NJ, Libbey JE, Wilcox KS, White HS, Fujinami RS. Innate but not adaptive immune responses contribute to behavioral seizures following viral infection. Epilepsia.
8. Stewart KAA, Wilcox KS, Fujinami RS, White HS. Theiler’s virus infection chronically alters seizure susceptibility. Epilepsia. 2010;51(8):1418–28.

9. Traynelis SF, Dlugos D, Henshall D, Mefford HC, Rogawski MA, Staley KJ, et al. Epilepsy Benchmarks Area III: Improved Treatment Options for Controlling Seizures and Epilepsy-Related Conditions Without Side Effects. Epilepsy Curr. 2020;20(1_suppl):23S-30S.

10. Tang F, Hartz AMS, Bauer B. Drug-resistant epilepsy: Multiple hypotheses, few answers. Front Neurol. 2017;8(JUL):1–19.

11. Löscher W. Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs. Seizure [Internet]. 2011;20(5):359–68. Available from: http://dx.doi.org/10.1016/j.seizure.2011.01.003

12. Wilcox KS, Gee JM, Gibbons MB, Tvrdik P, White JA. Altered structure and function of astrocytes following status epilepticus. Vol. 49, Epilepsy and Behavior. 2015.

13. Gibbons MB, Smeal RM, Takahashi DK, Vargas JR, Wilcox KS. Contributions of astrocytes to epileptogenesis following status epilepticus: Opportunities for preventive therapy? Neurochem Int [Internet]. 2013;63(7):660–9. Available from: http://dx.doi.org/10.1016/j.neuint.2012.12.008

14. Binder DK, Boison D, Eid T, Frankel WN, Mingorance A, Smith BN, et al. Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression. Epilepsy Curr. 2020;20(1_suppl):14S-22S.

15. Devinsky O, Vezzani A, Najjar S, De Lanerolle NC, Rogawski MA. Glia and epilepsy: Excitability and inflammation. Trends Neurosci [Internet]. 2013;36(3):174–84. Available from: http://dx.doi.org/10.1016/j.tins.2012.11.008
16. Patel DC, Tewari BP, Chaunsali L, Sontheimer H. Neuron–glia interactions in the pathophysiology of epilepsy. Nat Rev Neurosci [Internet]. 2019;20(5):282–97. Available from: http://dx.doi.org/10.1038/s41583-019-0126-4

17. Ge WP, Zhou W, Luo Q, Jan LY, Yuh NJ. Dividing glial cells maintain differentiated properties including complex morphology and functional synapses. Proc Natl Acad Sci U S A. 2009;106(1):328–33.

18. Larson VA, Zhang Y, Bergles DE. Electrophysiological properties of NG2+ cells: Matching physiological studies with gene expression profiles. Brain Res. 2016;1638.

19. Nishiyama A, Suzuki R, Zhu X. NG2 cells (polydendrocytes) in brain physiology and repair. Front Neurosci. 2014;8(8 JUN):1–7.

20. Nishiyama A, Boshans L, Goncalves CM, Wegrzyn J, Patel KD. Lineage, fate, and fate potential of NG2-glia. Vol. 1638, Brain Research. 2016.

21. Kirby L, Jin J, Cardona JG, Smith MD, Martin KA, Wang J, et al. Oligodendrocyte precursor cells present antigen and are cytotoxic targets in inflammatory demyelination. Nat Commun [Internet]. 2019;10(1):1–20. Available from: http://dx.doi.org/10.1038/s41467-019-11638-3

22. Okamura RM, Lebkowski J, Au M, Priest CA, Denham J, Majumdar AS. Immunological properties of human embryonic stem cell-derived oligodendrocyte progenitor cells. J Neuroimmunol. 2007;192(1–2):134–44.

23. Nakano M, Tamura Y, Yamato M, Kume S, Eguchi A, Takata K, et al. NG2 glial cells regulate neuroimmunological responses to maintain neuronal function and survival. Sci Rep. 2017;7(February):6–7.

24. Zhang SZ, Wang QQ, Yang QQ, Gu HY, Yin YQ, Li YD, et al. NG2 glia regulate brain
innate immunity via TGF-β2/TGFBR2 axis. BMC Med. 2019;17(1):1–22.

25. Paez PM, Lyons DA. Calcium Signaling in the Oligodendrocyte Lineage: Regulators and Consequences. Annu Rev Neurosci. 2020;43(1):163–86.

26. Libbey JE, Kirkman NJ, Wilcox KS, White HS, Fujinami RS. Role for Complement in the Development of Seizures following Acute Viral Infection. J Virol. 2010;84(13):6452–60.

27. Libbey JE, Kennett NJ, Wilcox KS, White HS, Fujinami RS. Interleukin-6, Produced by Resident Cells of the Central Nervous System and Infiltrating Cells, Contributes to the Development of Seizures following Viral Infection. J Virol. 2011;85(14):6913–22.

28. Libbey JE, Kennett NJ, Wilcox KS, White HS, Fujinami RS. Once initiated, viral encephalitis-induced seizures are consistent no matter the Treatment or lack of interleukin-6. J Neurovirol. 2011;17(5):496–9.

29. Barker-Haliski ML, Dahle EJ, Heck TD, Pruess TH, Vanegas F, Wilcox KS, et al. Evaluating an etiologically relevant platform for therapy development for temporal lobe epilepsy: Effects of carbamazepine and valproic acid on acute seizures and chronic behavioral comorbidities in the theiler’s murine encephalomyelitis virus mouse model. J Pharmacol Exp Ther. 2015;353(2):318–29.

30. Cusick MF, Libbey JE, Patel DC, Doty DJ, Fujinami RS. Infiltrating Macrophages Are Key to the Development of Seizures following Virus Infection. J Virol. 2013;87(3):1849–60.

31. Loewen JL, Barker-Haliski ML, Jill Dahle E, Steve White H, Wilcox KS. Neuronal injury, gliosis, and glial proliferation in two models of temporal lobe epilepsy. J Neuropathol Exp Neurol. 2016;75(4):366–78.

32. Patel DC, Wallis G, Jill Dahle E, McElroy PB, Thomson KE, Tesi RJ, et al. Hippocampal TNFα signaling contributes to seizure generation in an infection-induced mouse model of
limbic epilepsy. eNeuro. 2017;4(2).

33. Michalek J, Capek M, Janacek J. Stack Contrast Adjustment Plugin [Internet]. [cited 2020 Feb 27]. Available from: https://imagej.nih.gov/ij/plugins/stack-contrast/index.htm

34. Mauer CP, Bindokas V. 3d Hybrid Median Filter Plugin [Internet]. [cited 2020 Jun 8]. Available from: https://imagej.nih.gov/ij/plugins/hybrid3dmedian.html

35. Bourdoncle P. Colocalization Plugin [Internet]. [cited 2020 Jun 8]. Available from: https://imagej.nih.gov/ij/plugins/colocalization.html

36. Miller I, Min M, Yang C, Tian C, Gookin S, Carter D, et al. Ki67 is a Graded Rather than a Binary Marker of Proliferation versus Quiescence. Cell Rep. 2018;24(5).

37. Vargas JR, Takahashi DK, Thomson KE, Wilcox KS. The expression of kainate receptor subunits in hippocampal astrocytes after experimentally induced status epilepticus. J Neuropathol Exp Neurol. 2013;72(10):919–32.

38. Chancellor KB, Chancellor SE, Duke-cohan JE, Bertrand R. Altered oligodendroglia and astroglia in chronic traumatic encephalopathy. 2020;

39. Nagy C, Maitra M, Tanti A, Suderman M, Théroux JF, Davoli MA, et al. Single-nucleus transcriptomics of the prefrontal cortex in major depressive disorder implicates oligodendrocyte precursor cells and excitatory neurons. Nat Neurosci. 2020;

40. Hughes EG, Kang SH, Fukaya M, Bergles DE. Oligodendrocyte progenitors balance growth with self-repulsion to achieve homeostasis in the adult brain. Nat Neurosci. 2013;16(6).

41. McTigue DM, Wei P, Stokes BT. Proliferation of NG2-positive cells and altered oligodendrocyte numbers in the contused rat spinal cord. J Neurosci. 2001;21(10).
42. Jin X, Riew TR, Kim HL, Choi JH, Lee MY. Morphological characterization of NG2 glia and their association with neuroglial cells in the 3-nitropropionic acid-lesioned striatum of rat. Sci Rep. 2018;8(1).

43. Vanzulli I, Papanikolaou M, De La Rocha IC, Pieropan F, Rivera AD, Gomez-Nicola D, et al. Disruption of oligodendrocyte progenitor cells is an early sign of pathology in the triple transgenic mouse model of Alzheimer’s disease. Neurobiol Aging [Internet]. 2020;94:130–9. Available from: https://doi.org/10.1016/j.neurobiolaging.2020.05.016

44. Wu XL, Zhou JS, Wang LH, Liu JX, Hu HB, Zhang XT, et al. Proliferation of NG2 cells in the epileptic hippocampus. Epilepsy Res. 2019 May 1;152:67–72.

45. Sanz P, Garcia-Gimeno MA. Reactive glia inflammatory signaling pathways and epilepsy. Int J Mol Sci. 2020;21(11):1–17.

46. Wilcox KS, Vezzani A. Does brain inflammation mediate pathological outcomes in epilepsy? Advances in Experimental Medicine and Biology. 2014.

47. DePaula-Silva AB, Sonderregger FL, Libbey JE, Doty DJ, Fujinami RS. The immune response to picornavirus infection and the effect of immune manipulation on acute seizures. J Neurovirol. 2018;24(4).

48. Pan R, Zhang Q, Anthony SM, Zhou Y, Zou X, Cassell M, et al. Oligodendrocytes that survive acute coronavirus infection induce prolonged inflammatory responses in the CNS. Proc Natl Acad Sci [Internet]. 2020 Jul 7 [cited 2020 Jul 11];117(27):15902–10. Available from: https://www.pnas.org/content/117/27/15902

49. Fitch MT, Doller C, Combs CK, Landreth GE, Silver J. Cellular and molecular mechanisms of glial scarring and progressive cavitation: In vivo and in vitro analysis of inflammation-induced secondary injury after CNS trauma. J Neurosci. 1999;19(19):8182–
Damisah EC, Hill RA, Rai A, Chen F, Rothlin C V., Ghosh S, et al. Astrocytes and microglia play orchestrated roles and respect phagocytic territories during neuronal corpse removal in vivo. Sci Adv. 2020;6(26):eaba3239.

**Figure Legends**

**Figure 1**

Intracranial injection of Theiler murine encephalomyelitis virus (TMEV) leads to acute behavioral seizures. (A) Cumulatively, 93.75% of the TMEV-infected animals exhibited at least one stage 3 or greater seizure during the twice daily (AM & PM) observation periods. Cumulative percentage of mice that experienced stage 3 or greater seizures listed on top of bars. (B) On any given day, the percentage of mice exhibiting a stage 3 or greater seizure ranged between 37-87% during any individual observation period. As half the total TMEV-infected mice (n=16) were sacrificed after the observation period on 4 dpi, the number of mice observed from 5-7 dpi was reduced to n=8. Number of seized and non-seized mice listed in bars. (C) The total numbers of seizures observed based on the modified Racine scale on each day during seizure monitoring show the seizure intensity increases over the course of the observation period. Number of seizures listed above bars.

**Figure 2**

Imaging brain regions of interest. Low magnification (4x) confocal image showing NG2 (green) and microglia/macrophage marker ionized calcium-binding adaptor molecule 1 (IBA) (red) in a TMEV-infected mouse brain at 4 dpi. White boxes identify representative imaging regions of
interest in the cortex and the CA1 region of the hippocampus. SO = stratum oriens, SP = stratum pyramidal, SR = stratum radiatum. Scale bar = 100 µm.

**Figure 3**

TMEV-injected animals exhibit reactive NG2 cells and microglia/macrophages in the hippocampus at 4 dpi. (A) NG2 cells (green) and microglia/macrophages (red) in the CA1 region of the hippocampus of PBS-injected (top) and TMEV-injected (bottom) mice at 4 dpi. (B) TMEV-injected mice showed significantly greater immunoreactivity for NG2 compared to PBS-injected mice. (C) TMEV-injected mice showed significantly greater immunoreactivity for IBA1 compared to PBS-injected mice. All images are 20x maximum-intensity projections of 12 µm confocal z-stacks. Scale bars = 100 µm.

**Figure 4**

TMEV-injected animals exhibit scarring and reactive NG2 cells and microglia/macrophages in the hippocampus at 14 dpi. (A) NG2 cells (green) and microglia/macrophages (red) in the CA1 region of the hippocampus of PBS-injected (top) and TMEV-injected (bottom) mice at 14 dpi. (B) TMEV-injected mice showed significantly greater immunoreactivity for NG2 compared to PBS-injected mice. (C) TMEV-injected mice showed significantly greater immunoreactivity for IBA1 compared to PBS-injected mice. Images are 20x maximum-intensity projections of 12 µm confocal z-stacks. Scale bars = 100 µm.

**Figure 5**

In contrast to microglia, NG2 cells in the cortex of TMEV-injected animals do not exhibit reactivity at 4 dpi. (A) NG2 cells (green) and microglia/macrophages (red) in the cortex of PBS-
injected (top) and TMEV-injected (bottom) mice at 4 dpi. (B) TMEV-injected mice did not show significant changes in immunoreactivity for NG2 compared to PBS-injected mice. (C) TMEV-injected mice showed significantly greater immunoreactivity for IBA1 compared to PBS-injected mice. Images are 20x maximum-intensity projections of 12 µm confocal z-stacks. Scale bars = 100 µm.

**Figure 6**

NG2 cells, in contrast to microglia, do not exhibit increased reactivity in the cortex at 14 dpi. (A) NG2 cells (green) and microglia/macrophages (red) in the cortex of PBS-injected (top) and TMEV-injected (bottom) mice at 4 dpi. (B) TMEV-injected mice did not show significant changes in immunoreactivity for NG2 compared to PBS-injected mice. (C) TMEV-injected mice showed significantly greater immunoreactivity for IBA1 compared to PBS-injected mice. Images are 20x maximum-intensity projections of 12 µm confocal z-stacks. Scale bars = 100 µm.

**Figure 7**

NG2 cell proliferation is increased in the hippocampus of TMEV-injected animals at 4 and 14 dpi. (A) NG2 cells (green) and proliferation marker Ki-67 (red) in the CA1 hippocampal region of PBS-injected (Top) and TMEV-injected (bottom) mice at 4 and 14 dpi. Arrow heads point to cells containing pixels colocalized for both NG2 and Ki-67. (B) There is a significant increase in colocalization of NG2 and Ki-67 in the CA1 region of the hippocampus of TMEV-injected mice compared to PBS-injected mice at 4 dpi. (C) There is also significant increase in colocalization of NG2 and Ki-67 in the CA1 region of the hippocampus of TMEV-injected mice compared to PBS-injected mice at 14 dpi. Images are 20x maximum-intensity projections of 12 µm confocal z-stacks. All scale bars = 50 µm.
Figure 8

NG2 cell proliferation is not significantly changed in the cortex of TMEV-injected animals at both 4 and 14 dpi. (A) NG2 cells (green) and proliferation marker Ki-67 (red) in the cortex of PBS-injected (top) and TMEV-injected (bottom) mice at 4 and 14 dpi. Arrow heads point to cells containing pixels colocalized for both NG2 and Ki-67. (B) There is no significant change in colocalization of NG2 and proliferation marker Ki-67 in the cortex of TMEV-injected animals at 4 dpi. (C) There is also no significant change in colocalization of NG2 and Ki-67 in the cortex of TMEV-injected animals at 14 dpi. Images are 20x maximum-intensity projections of 12 µm confocal z-stacks. Scale bars = 50 µm.